Similarly, a prospective study conducted by Di Nardo et al. demonstrated that the VEN–AZA combination can induce deep molecular responses in patients with IDH2- or NPM1-mutated AML [15]. This evidence concerns the gene NPM1 and acute myeloid leukemia.